The response to growth hormone (GH) therapy for short stature is extremely variable and growth response targets remain poorly defined. This study used data from the Genentech National Cooperative ...
Please provide your email address to receive an email when new articles are posted on . Somapacitan-beco improved multiple growth-related endpoints for adolescents with four types of short stature.
Please provide your email address to receive an email when new articles are posted on . Daily ibutamoren was noninferior to recombinant human GH at 12 months for children with moderate GH deficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results